Literature DB >> 9566119

SH3 domains and drug design: ligands, structure, and biological function.

D C Dalgarno1, M C Botfield, R J Rickles.   

Abstract

The ligand binding preferences, structural features, and biological function of SH3 (Src homology 3) domains are discussed. SH3 domains bind "core" Pro-rich peptide ligands (7-9 amino acids in length) in a polyproline II helical conformation in a highly conserved aromatic rich patch on the protein surface (approximately 390 A2). The ligands can interact with the protein in one of two orientations, depending on the position (N- vs C-terminal) of ligand residues binding to the SH3 selectivity pocket. Core SH3 ligands are characterized by relatively weak interactions (KD = 5-100 microM) that show little binding selectivity within SH3 families. Higher affinity, more selective contiguous ligands require additional flanking residues that bind to less conserved portions of the SH3 surface, with corresponding increase in ligand size and complexity. In contrast to peptide ligands, protein ligands of SH3 domains can exploit multiple discontiguous interactions to enhance affinity and selectivity. A protein-SH3 interaction that utilizes unique interactions may permit the design of small high affinity SH3 ligands. At present, the extended nature of the binding site and homologous nature of the core binding region among SH3 domains present key challenges for structure-based drug design.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9566119     DOI: 10.1002/(SICI)1097-0282(1997)43:5<383::AID-BIP4>3.0.CO;2-R

Source DB:  PubMed          Journal:  Biopolymers        ISSN: 0006-3525            Impact factor:   2.505


  43 in total

1.  The identification of conserved interactions within the SH3 domain by alignment of sequences and structures.

Authors:  S M Larson; A R Davidson
Journal:  Protein Sci       Date:  2000-11       Impact factor: 6.725

2.  The design of a hyperstable mutant of the Abp1p SH3 domain by sequence alignment analysis.

Authors:  A Rath; A R Davidson
Journal:  Protein Sci       Date:  2000-12       Impact factor: 6.725

Review 3.  Viral late domains.

Authors:  Eric O Freed
Journal:  J Virol       Date:  2002-05       Impact factor: 5.103

4.  Ligand-induced changes in dynamics in the RT loop of the C-terminal SH3 domain of Sem-5 indicate cooperative conformational coupling.

Authors:  Josephine C Ferreon; Vincent J Hilser
Journal:  Protein Sci       Date:  2003-05       Impact factor: 6.725

5.  Synaptic targeting of N-type calcium channels in hippocampal neurons.

Authors:  Anton Maximov; Ilya Bezprozvanny
Journal:  J Neurosci       Date:  2002-08-15       Impact factor: 6.167

6.  Limitations of peptide retro-inverso isomerization in molecular mimicry.

Authors:  Chong Li; Marzena Pazgier; Jing Li; Changqing Li; Min Liu; Guozhang Zou; Zhenyu Li; Jiandong Chen; Sergey G Tarasov; Wei-Yue Lu; Wuyuan Lu
Journal:  J Biol Chem       Date:  2010-04-09       Impact factor: 5.157

7.  Fcp1 directly recognizes the C-terminal domain (CTD) and interacts with a site on RNA polymerase II distinct from the CTD.

Authors:  Man-Hee Suh; Ping Ye; Mincheng Zhang; Stéphane Hausmann; Stewart Shuman; Averell L Gnatt; Jianhua Fu
Journal:  Proc Natl Acad Sci U S A       Date:  2005-11-21       Impact factor: 11.205

8.  Structural basis of Robo proline-rich motif recognition by the srGAP1 Src homology 3 domain in the Slit-Robo signaling pathway.

Authors:  Xiaofeng Li; Yushu Chen; Yiwei Liu; Jia Gao; Feng Gao; Mark Bartlam; Jane Y Wu; Zihe Rao
Journal:  J Biol Chem       Date:  2006-07-20       Impact factor: 5.157

9.  "Fuzzy oil drop" model applied to individual small proteins built of 70 amino acids.

Authors:  Katarzyna Prymula; Kinga Sałapa; Irena Roterman
Journal:  J Mol Model       Date:  2010-01-19       Impact factor: 1.810

10.  Human melanoma inhibitory protein binds to the FN12-14 Hep II domain of fibronectin.

Authors:  King Tuo Yip; Xueyin Zhong; Nadia Seibel; Oliver Arnolds; Miriam Schöpel; Raphael Stoll
Journal:  Biointerphases       Date:  2017-05-31       Impact factor: 2.456

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.